NEOSENT: Early Anti-PD-1 Therapy In High-Risk Stage II Melanoma

Recruiting now

Conditions studied: Cutaneous Melanoma

In brief

This is an observational cohort study evaluating clinical and pathological outcomes in patients with high-risk stage II melanoma. Patients are included after receiving treatment as part of routine clinical practice. Decisions about treatment, including whether to start anti-PD1 therapy before surgery, are made by the treating physician and are not influenced by the study. The study compares outcomes between patients who started anti-PD1 therapy before surgery and those treated according to the usual timing in clinical practice. No treatments are assigned as part of the study.

Key facts

Study ID

NCT07680699

Run by

AC Camargo Cancer Center

People needed

250

Starts

2025-04-23

Expected to finish

2027-05-01

Last updated by the study team

2026-07-02

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults (≥18 years) with histologically confirmed cutaneous melanoma stage IIB or IIC or stage III (N1c), managed in routine clinical practice.

You may not qualify if…

• Patients without sufficient clinical or follow-up data.
• Patients who do not provide informed consent (for prospective cohort).

Where it is running

• AC Camargo Cancer Center — São Paulo, São Paulo, Brazil (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.